Verve’s gene-editing therapy trial to lower cholesterol levels opens doors for use in CVDs: GlobalData Read more
SPARC completes enrolment in PROSEEK, Phase 2 study of Vodobatinib in early Parkinson’s disease Read more
Termination of Ultragenyx’s UX053 Phase I/II study is a minor setback for mRNA therapeutics: GlobalData Read more
Stempeutics concludes patient enrollment for Phase 3 cell therapy trial for diabetic foot ulcer Read more